The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData.

Tapinarof, an aryl hydrocarbon receptor modulator that has been observed to have anti-inflammatory effects, has been marketed for plaque psoriasis in adults. It employs the binding of aryl hydrocarbon receptors to decrease proinflammatory cytokines, decrease oxidative stress, and promote skin barrier normalization, according to GlobalData.

Clinical trials have shown good tolerance with minimal adverse effects in patients with atopic dermatitis, GlobalData says.